ANAPTYSBIO (ANAB) reports ownership of 100 First Tracks Biotherapeutics shares

Rhea-AI Filing Summary

ANAPTYSBIO, INC, identified as a ten percent owner of First Tracks Biotherapeutics, Inc., filed an initial ownership report. In connection with the spin-off of First Tracks under a Separation and Distribution Agreement dated April 1, 2026, ANAPTYSBIO owns all 100 outstanding shares of First Tracks common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ANAPTYSBIO, INC

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 100 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Form type: Form 3 Shares owned: 100 shares Spin-off date: April 1, 2026

3 metrics

Form type Form 3 Initial statement of beneficial ownership

Shares owned 100 shares Outstanding shares of First Tracks common stock owned by ANAPTYSBIO

Spin-off date April 1, 2026 Date of Separation and Distribution Agreement and spin-off

Key Terms

spin-off, Separation and Distribution Agreement, outstanding shares of common stock, ten percent owner

4 terms

spin-off financial

"In connection with the spin-off of First Tracks Biotherapeutics, Inc."

A spin-off happens when a company creates a new, independent business by separating part of itself, like splitting off a division into its own company. This often happens so the new company can focus better on its own goals or attract different investors. It matters because it can lead to more growth opportunities and clearer focus for both companies.

Separation and Distribution Agreement financial

"as defined in the Separation and Distribution Agreement, dated April 1, 2026"

outstanding shares of common stock financial

"owns all 100 outstanding shares of common stock of First Tracks"

ten percent owner regulatory

"Reporting Person is marked as a ten percent owner"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ANAPTYSBIO, INC

(Last) (First) (Middle)

10770 WATERIDGE CIRCLE, SUITE 210

(Street)

SAN DIEGO CALIFORNIA 9212

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
First Tracks Biotherapeutics, Inc. [ TRAX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	100(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. In connection with the spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks") by the Reporting Person, as defined in the Separation and Distribution Agreement, dated April 1, 2026, between the Reporting Person and First Tracks, a wholly owned subsidiary of the Reporting Person, the Reporting Person on April 1, 2026 owns all 100 outstanding shares of common stock of First Tracks.

	/s/ Dan Faga	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What ownership in First Tracks Biotherapeutics does ANAPTYSBIO, INC report?

ANAPTYSBIO, INC reports ownership of all 100 outstanding shares of common stock of First Tracks Biotherapeutics, Inc. This reflects its entire equity position in First Tracks as described in the filing’s ownership table and related footnote.

How is ANAPTYSBIO, INC related to First Tracks Biotherapeutics, Inc. (ANAB)?

First Tracks Biotherapeutics, Inc. is described as a wholly owned subsidiary of ANAPTYSBIO, INC. The filing notes that ANAPTYSBIO holds all 100 outstanding shares of First Tracks common stock as of the referenced date.

What transaction is associated with ANAPTYSBIO’s First Tracks holdings on April 1, 2026?

The filing ties ANAPTYSBIO’s First Tracks holdings to a spin-off effective April 1, 2026. Under a Separation and Distribution Agreement dated that day, ANAPTYSBIO owns all 100 outstanding shares of First Tracks common stock.

Why does ANAPTYSBIO, INC qualify as a ten percent owner in this filing?

ANAPTYSBIO, INC is identified as a ten percent owner because it holds all 100 outstanding shares of First Tracks Biotherapeutics common stock. This complete ownership stake meets the threshold for ten percent owner status in the report.

What agreement governs the spin-off of First Tracks Biotherapeutics from ANAPTYSBIO?

The relationship is governed by a Separation and Distribution Agreement dated April 1, 2026 between ANAPTYSBIO, INC and First Tracks Biotherapeutics, Inc. The agreement is referenced in the footnote describing the spin-off and resulting share ownership.